COMPANY

Cessation Therapeutics

Keywords: antibody monoclonal antibody Opioid Overdose Opioid Use Disorder CSX-1004

Location: San Jose, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $2.09M (NIH grant 5U01DA063352-02, continuation, notice Aug 25, 2026). NIH RePORTER 5U01DA063352-02 (Aug 25, 2026)
Evidence (1 event)
- Aug 25, 2026 · NIH RePORTER 5U01DA063352-02
  Organization: CESSATION THERAPEUTICS, LLC; City/State: SAN JOSE, CA; Project number: 5U01DA063352-02; Activity code: U01; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 2089891; Administering IC: National Institute on Drug Abuse; Project title: Development of the anti-fentanyl monoclonal antibody, CSX-1004, for prophylaxis against fentanyl and fentanyl analog overdose; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Aug 25, 2026 Grant Government grant — NIH U01: $2.09M (annual award, as published), announced Aug 25, 2026. Agency: NIH/NIDA. Source: government award database. source ↗
Sep 2, 2025 Grant Government grant — NIH U01: $2.61M (annual award, as published), announced Sep 2, 2025. Agency: NIH/NIDA. Source: government award database. source ↗
Aug 1, 2023 Trial start Phase 1: Safety, Tolerability, and Pharmacokinetics of CSX-1004 source ↗

Last 2 years.

Aug 25, 2026 Government grant — NIH U01: $2.09M (annual award, as published), announced Aug 25, 2026. Agency: NIH/NIDA. Source: government award database. source ↗
Sep 2, 2025 Government grant — NIH U01: $2.61M (annual award, as published), announced Sep 2, 2025. Agency: NIH/NIDA. Source: government award database. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT06005402	Safety, Tolerability, and Pharmacokinetics of CSX-1004	Phase 1	Completed	Aug 1, 2023	May 28, 2024 (actual)

Annual award amounts. Total $7.3M.

Aug 27, 2021 NIH award 5U01DA051071-02 FY2021: $1,022,571 awarded for that fiscal year; activity U01 (OTHER_NIH); PI BREMER, PAUL T; recipient as written: CESSATION THERAPEUTICS, LLC, SAN JOSE, CA. Process Development, Manufactur source ↗
Sep 25, 2020 NIH award 1U01DA051071-01A1 FY2020: $6,107,502 awarded for that fiscal year; activity U01 (OTHER_NIH); PI BREMER, PAUL T; recipient as written: CESSATION THERAPEUTICS, LLC, SAN JOSE, CA. Process Development, Manufact source ↗
May 24, 2019 NIH award 1R43DA048720-01 FY2019: $211,174 awarded for that fiscal year; activity R43 (SBIR); PI BREMER, PAUL T; recipient as written: CESSATION THERAPEUTICS, LLC, SAN JOSE, CA. Development of Therapeutic Anti-Nicoti source ↗